Guardant Health, Inc. (GH) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
the bull case· 2
6
disclosed supplier and customer ties in SEC filings
sec filingsedgar595
managers reporting a position in thirteen F filings
13fJun 30 '26the bear case· 4
12 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26−8.88%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '267 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized52
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 4 '26 report. Not a forecast, not advice.
Of the 6 companies Guardant Health, Inc. moves with most closely, 2 also share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 8071, Services-Medical Laboratories, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›tall tick = annual report · 1 on record
GH (Guardant Health, Inc.) has 1 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
597 managers report a position worth $20.4B between them, and 52 of them hold 80% of it.
High 178.74 at 9:30 am ET, low 175.00 at 4:15 am ET.
Guardant Health, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Services-Medical Laboratories